Development of a novel anti‐amyloid therapeutic: an orally administrable anti‐abeta‐oligomer compound in early preventative intervention
Our findings demonstrate that oral administrated D-AIP effectively targeted Aβ oligomers to prevent AD-associated deposition and neurotoxicity in an AD mouse model at very early stages of amyloid deposition. Since orally delivered D-AIP had no observable adverse effect it presents great promise as a next-generation AD therapeutic.
Authors
- Mark A. Hancock (ORCID: https://orcid.org/0000-0001-7427-7449)
- Medhinee M. Malvankar
- Pei You Wu (ORCID: https://orcid.org/0000-0002-9732-4663)
- Adeola Shobo (ORCID: https://orcid.org/0000-0002-2846-323X)
- Thierry Choquette (ORCID: https://orcid.org/0000-0002-5715-6335)
- Hedi Zhou (ORCID: https://orcid.org/0000-0002-4871-2635)
- Sara Touj
- Mallar Chakravarty
- Louis‐Charles Masson
- Rebecca Anne McKinney
- Gerhard Multhaup
- Fatima El Ansari
Institutions
- Douglas Mental Health University Institute (CA)
- McGill University (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_101967
- Primary Topic
- Amino Acid Enzymes and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00